The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.
New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.
Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.
PureHealth Research has launched the Natural GLP-1 Support collection, providing a comprehensive, needle-free alternative to expensive synthetic GLP-1 injections. Led by the physician-approved GLP ON formula, it addresses three key GLP-1 pathways with clinically studied dosages. Discover how these natural supplements support weight management and metabolic function without prescriptions.
Lab mice shed pounds when key amino acids—methionine and cysteine—were cut from their diet, igniting fat burning without exercise. A University of Southern Denmark study shows this diet-induced thermogenesis boosted calorie burn by 20%, nearly matching constant cold exposure. This could redefine obesity treatments beyond GLP-1 drugs.
Millionaire Gemma Collins is flogging her once-worn clothes on Vinted after shedding 3 stone with Mounjaro injections. From size 26 to 20, the TOWIE star shares how the jabs curbed her food obsession. But a gallbladder scare paused her treatment—here's her full story.
Tess Holliday, a prominent body positivity advocate, shared her shocking experience of being denied life insurance solely because she weighs over 300 pounds at 5 foot 3, despite no pre-existing conditions or medications. Her story highlights deep-rooted fatphobia in the insurance and medical systems. Amid GLP-1 drugs like Ozempic promoting thin ideals, she relaunches #EffYourBeautyStandards to fight back.
A safety alert from the MHRA warns of counterfeit Mounjaro pens distributed to the public, posing risks due to unknown sterility despite containing tirzepatide. Five affected pens were supplied through a Birmingham pharmacy, with defects like detaching dose knobs reported. Check your batch number and stop use immediately if impacted.
Abbott has tied up with Novo Nordisk India to commercialize Extensior, the second brand of semaglutide injection following Ozempic's launch. This move positions Abbott as the second firm with sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma. With demand surging and generics on the horizon, here's what it means for patients.
